AstraZeneca's blockbuster cancer drug Imfinzi has experienced mixed outcomes in recent clinical trials. The drug failed to improve disease-free survival in a late-stage trial for early-stage lung cancer, marking a significant setback for its use as an adjuvant therapy in non-small cell lung cancer (NSCLC). This failure follows the quiet setbacks of the Mermaid-1 and Mermaid-2 trials. However, Imfinzi demonstrated a statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in the NIAGARA Phase III trial. Additionally, China's National Medical Products Administration has approved AstraZeneca's Tagrisso in combination with chemotherapy as a first-line treatment for advanced lung cancer, further bolstering the company's oncology portfolio.
Listen to @MikkaelSekeres, of @SylvesterCancer, as he discusses preliminary outcomes with oral azacitidine in lower-risk myelodysplastic syndromes, as reported in the ASTREON trial. #oncology #hematology https://t.co/45lGFMtjlC
Listen to @Daver_Leukemia, of @MDAndersonNews, as he discusses the future of targeted therapy development for patients with acute myeloid #leukemia. #AML https://t.co/fJbOR2dMfa
Amivantamab, an antibody against MET and EGFR, plus lazertinib, an EGFR tyrosine kinase inhibitor, induced a response in 86% of previously untreated patients and led to a median progression-free survival of nearly 2 years. Full MARIPOSA trial results: https://t.co/QHsu24YpnN https://t.co/Zcv1umOnfY
Cetuximab Biosimilar Receives NMPA Approval For RAS/BRAF Wild-Type CRC #crcsm #oncology https://t.co/X3BC9qOBi6
Dizal expects to file for AA in treated EGFR exon20 insertion-mutated NSCLC despite Rybrevant full approval https://t.co/rDE2Z0LU79
Mitazalimab Plus mFOLFIRINOX Yields 18-Month OS Benefit in Previously Untreated Metastatic Pancreatic Cancer #pancsm #oncology https://t.co/BiPKCj7Qj2
China’s NMPA Approves First-Line Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC #lcsm #oncology https://t.co/iAxv67qMQE
After $ONCT revealed 1 death (CRS & ICANS) in 4 patients given ONCT-808, $LYEL says 1 of 18 patients given LYL797 died of pneumonitis. @ApexOnco take on today's sketchy Ror1 Car-T data: https://t.co/BX3EP4D4SE
A death and other adverse events have forced Lyell Immunopharma to take a two-track approach to its early-phase CAR-T clinical trial. $LYEL https://t.co/QWCi0Q2QlS
A lesson here: read the whole release to the end. Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology https://t.co/uZ085kmFUk
Everything I know about $LLY's two Nectin-4 ADCs (and other first-in-human study initiations), via @ApexOnco -> https://t.co/fUDYyTyzzB $REGN $TSVT $CRBS
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology $LYEL https://t.co/WlAdrdR1Xc
Eric Winer, MD, discusses the safety and efficacy outcomes of the TakeAim Leukemia trial and future research with emavusertib in combination therapies. @DanaFarber #leusm #oncology https://t.co/nmagl5noDi
Toripalimab plus bevacizumab significantly improved PFS and OS vs sorafenib, and revealed no new safety signals in patients with advanced HCC. #oncology https://t.co/suho7K8cwu https://t.co/e2J6432fv8
China approved @AstraZeneca 's Tagrisso with the addition of pemetrexed and platinum-based chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor, receptor-mutated, non-small cell lung cancer, the pharma giant said today.
. @AstraZeneca’s Imfinzi fails an adjuvant #lungcancer trial, but a win in #bladdercancer takes the edge off that disappointment. #oncology https://t.co/I7j44olODe
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment https://t.co/wbmPWu9Ryl https://t.co/e41wWlWdmN
China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said on Wednesday. https://t.co/RzUP6uVPSk https://t.co/RzUP6uVPSk
China approved @AstraZeneca's Tagrisso with the addition of pemetrexed and platinum-based chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor, receptor-mutated, non-small cell lung cancer, the pharma giant said today. https://t.co/zlGLKHRP66
Versamune HPV plus pembrolizumab showed a median OS of 30.0 months in checkpoint inhibitor–naive patients with HPV16-positive recurrent/metastatic HNSCC. #hnscc #oncology https://t.co/kQq0YN5hgD
Talquetamab generated responses and was safe in patients with relapsed/refractory multiple myeloma who received prior treatment with T-cell–directed therapies, including in those with other medical conditions or poor functional status. @ASCO #ASCO24 #mmsm https://t.co/UWKNuH6qw2
China approves CSPC Pharma mRNA cancer therapy for clinical trials https://t.co/UUsxFEQ11h https://t.co/XBBnejkBqG
Long-term data from clinical trials presented at the 2023 ASH Annual Meeting added further insight to frontline treatment selections for patients with CLL/SLL. @UPMCHillmanCC #leusm #oncology https://t.co/gjmWPyNpWA
In the phase 1 AMPLIFY-7P trial, the adjuvant lymph node–targeted amphiphile vaccine ELI-002 7P was well tolerated and bolstered mKRAS–specific T-cell responses in patients with MRD–positive pancreatic and colorectal cancers. @ASCO #ASCO24 #pancsm #crcsm https://t.co/KdmqHosDKM https://t.co/O5Gw8DhlgV
A recent study demonstrated the clinical benefit of #tafasitamab as an early-line treatment for relapsed/refractory diffuse large B-cell #lymphoma. Keep reading: https://t.co/YLREAKVtfB #DLBCL #CancerResearch https://t.co/Xh1nxRtqW1
AstraZeneca's Imfinzi counts a trial win in bladder cancer, a miss in lung cancer https://t.co/OU9TQYsrKY
First effective use of immunotherapy for the most common subtype of #ColorectalCancer reported in @NatureMedicine. This early-stage research shows promise for metastatic disease. #CancerResearch #ClinicalTrial CC: @DanaFarber @ben_schlechter Read more: https://t.co/QhxtjSoy6L https://t.co/wjPOtfaL2B
First-Line Osimertinib Plus Chemo Approved in Japan for EGFR+ Advanced NSCLC #lcsm #oncology https://t.co/ldPbGBQJnq
First-Line Toripalimab Plus Chemo Wins Approval in China for Advanced TNBC #oncology #bcsm https://t.co/NILEDZSwZ9
Adjuvant Durvalumab Misses DFS End Point in Resected, PD-L1+ Stage IB-IIIA NSCLC #lcsm #oncology https://t.co/1FaMFbBIY9
Perioperative Durvalumab Plus Chemo Meets EFS, OS End Points in MIBC @tompowles1 #blcsm #oncology https://t.co/FcO0rO7efF
Linvoseltamab Displays Durable Efficacy in Relapsed/Refractory Multiple Myeloma @OSUCCC_James #mmsm https://t.co/6zPfSmCKVN
#GSK’s Blenrep for #multiplemyeloma had turn around data at #ASCO24 and editor-in-chief Jonah Comstock met with Dr Suzanne Trudel, the principal investigator on the redemptive DREAMM-8 study, to discuss. #video https://t.co/38VRL35JIy
That was possibly $AZN Imfinzi's last shot at adjuvant NSCLC. Note quiet failures of Mermaid-1 & 2. Aegean & CM-77T filings are effectively for neoadjuant use. https://t.co/SPu2mivd65
End of the road for Imfinzi in adjuvant NSCLC? $AZN https://t.co/tJf7xWrXwY https://t.co/NLz3txFekc
Phase 2 trial of CD19 CAR T-cell therapy #lisocabtagene maraleucel in patients with second line or later relapsed or refractory follicular #lymphoma, show encouraging objective response rates, including in highrisk second-line patients. https://t.co/EkiGeLsEhG
China's National Drug Administration has granted Merck's KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country. https://t.co/LjqgdZzjRm https://t.co/LjqgdZzjRm
AstraZeneca's blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a type of early-stage lung cancer, the group said on Tuesday. https://t.co/twyomTuUsp https://t.co/twyomTuUsp
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial $AZN https://t.co/QngZ2j0G3t
Zanidatamab's BLA for HER2-positive biliary tract cancer accepted by China's NMPA, supported by phase 2b HERIZON-BTC-01 trial results. #oncology #medtwitter https://t.co/2HXkA6L7tF
Alectinib significantly improved DFS in ALK-positive NSCLC patients compared to platinum-based chemotherapy. @EU_Commission #lcsm #oncology https://t.co/DnJXPYQ7b8 https://t.co/4bJYDRzk3K
AstraZeneca's Imfinzi fails in late-stage trial to treat certain type of lung cancer https://t.co/fLbzcTTHoW https://t.co/hG9eOwIrE6
AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer. https://t.co/utp169xKSo https://t.co/utp169xKSo
A phase 2a study evaluating the CDK9 inhibitor SLS009 as treatment for patients with relapsed/refractory AML has completed enrollment and positive initial data have been shared. #oncology #leusm https://t.co/rz38Kjsm1w https://t.co/2J8LKHzlpz